Introduction {#Sec1}
============

One of the possible causes of biliary tract cancer may be chronic and continuous stimulation of the biliary tract, and cholangitis due to gallstones and the reflux of pancreatic juice into the biliary tract.[@CR1],[@CR2] The underlying diseases that potentially cause such a condition include pancreaticobiliary maljunction (PBM),[@CR3] primary sclerosing cholangitis (PSC),[@CR4]--[@CR7] chronic cholecystitis,[@CR1] gallstones,[@CR1],[@CR8] and adenomyomatosis.[@CR9] In such patients, chronic inflammation potentially causes pathological changes of the biliary epithelium resulting in precursors of biliary tract cancer.[@CR1]

Although curative resection is the only treatment for biliary tract cancer that achieves long-term survival, patients with advanced cancer have only a limited prognosis even after radical surgical resection. To improve the long-term results, therefore, the early detection of precancerous and cancerous lesions, and subsequent cure seem to be essential.

In this article, we discuss the predisposing factors for bile duct cancer, gallbladder cancer, and ampullary carcinoma, using a format of clinical questions (CQs) and responses. In the responses to the CQs, recommendations for treatment are noted (grades of these recommendations are defined in Table [1](#Tab1){ref-type="table"}[@CR10]). Also, levels of evidence are given (in parentheses) for findings in reference citations (see definitions of levels in Table [2](#Tab2){ref-type="table"}[@CR10]). Table 1Strength of recommendations[@CR10]A, Strongly recommend performing the clinical actionB, Recommend performing the clinical actionC1, The clinical action may be considered although there is a lack of high-level scientific evidence for its use. May be usefulC2, Clinical action not definitively recommended because of insufficient scientific evidence. Evidence insufficient to support or deny usefulnessD, Recommend not performing the clinical actionTable 2Levels of evidence[@CR10]Level ISystematic review/meta-analysisLevel IIOne or more randomized clinical trialsLevel IIINonrandomized controlled trialsLevel IVAnalytic epidemiology (cohort studies and case-control studies)Level VDescriptive study (case reports and case-series studies)Level VIOpinions of expert panels and individual experts not based on patient's data

CQ 1 What are the risk factors for biliary tract and ampullary carcinomas? {#Sec2}
==========================================================================

Pancreaticobiliary maljunction (PBM) with bile duct dilatation and primary sclerosing cholangitis (PSC) are risk factors for biliary tract cancer (see side memos 1 and 2). PBM, particularly that without bile duct dilatation, is a risk factor for gallbladder cancer.

There are no evident risk factors for ampullary carcinoma.

The prevalence rate of biliary tract cancer varies in different geographical regions. Chile and Japan have the highest rate in the world, followed by East Asia and India (level V).[@CR1],[@CR2] Also, there are age differences in the incidence of biliary tract cancer.[@CR1] It has been reported that the risk factors for biliary tract cancer are, possibly, chronic and continuous stimulation and inflammation of the biliary tract.[@CR1],[@CR2] Polypoid lesions of the gallbladder and adenomyomatosis have been regarded as a risk factors for gallbladder cancer. In this section, we review the respective risk factors for bile duct cancer, gallbladder cancer, and ampullary carcinoma.

Risk factors for bile duct cancer {#Sec3}
=================================

Pancreaticobiliary maljunction (see CQ 2) {#Sec4}
-----------------------------------------

A retrospective nationwide survey (1990 to 1999) of PBM in Japan revealed that 10.6% of PBM patients with bile duct dilatation were complicated by biliary tract cancer, and 33.6% of these biliary tract cancers were bile duct cancer[@CR3] (level IV). PBM with bile duct dilatation is considered as a risk factor for bile duct cancer.

Primary sclerosing cholangitis (PSC) {#Sec5}
------------------------------------

Patients wit PSC carry an increased risk of bile duct cancer. Five percent to 10% of PSC patients develop bile duct cancer[@CR4]--[@CR7] (level V). Bile duct cancer associated with PSC is often advanced with a poor prognosis. PSC, therefore, should be recognized as a risk factor for bile duct cancer.

Controversy remains as to whether bile duct cancer is related to chronic inflammation due to gallstones or some gene mutations[@CR8],[@CR11],[@CR12] (level IV).

Risk factors for gallbladder cancer {#Sec6}
===================================

Pancreaticobiliary maljunction (see CQ 2) {#Sec7}
-----------------------------------------

There have been many studies that reported PBM as a risk factor for gallbladder cancer. A nationwide survey (1990 to 1999) of PBM revealed that the prevalence rate of biliary tract cancer was 10.6% in the group with bile duct dilatation, while the prevalence rate was 37.9% in the group without bile duct dilatation[@CR3] (level IV). With respect to the PBM patients who developed biliary tract cancer, the incidence of gallbladder cancer was 64.9% in those with PBM with bile duct dilatation, whereas the incidence was 93.2% in those with PBM without bile duct dilatation. Therefore, PBM is an evident risk factor for gallbladder cancer. Of note, the frequency of gallstones in patients with PBM associated with gallbladder cancer is low.[@CR13]

Gallstones and porcelain gallbladder (see CQ 3) {#Sec8}
-----------------------------------------------

It has been well established that gallstones are closely associated with gallbladder cancer[@CR1],[@CR8] (level V). It has also been reported that a stone size of more than 3 cm, a family history of gallbladder cancer, and the duration of cholelithiasis are potential risk factors for developing gallbladder cancer.[@CR1],[@CR14]--[@CR16] However, there is no evidence of a direct causal relationship between gallstones and gallbladder cancer. Gracie and Ransohoff[@CR17] followed-up the subsequent history of 123 patients with asymptomatic gallstones for 10 years or longer, and revealed that there was no case of gallbladder cancer reported among that group.

Controversy remains as to whether patients with "porcelain gallbladder" carry a risk of gallbladder cancer. It has been reported that porcelain gallbladder is often complicated by gallbladder carcinoma[@CR18],[@CR19] (level IV), while another report suggests that porcelain gallbladder is not associated with gallbladder carcinoma[@CR20] (level IV).

Adenoma of the gallbladder (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}; also see CQ 4) {#Sec9}
-----------------------------------------------------------------------------------------------------------

There is consensus regarding the existence of two models through which malignant transformation is produced: the adenoma-carcinoma sequence and the dysplasia-carcinoma sequence. Intestinal and gastric metaplasias appear to be the pathway through which epithelial dysplasia is produced.[@CR21] Yamagiwa[@CR22] examined 110 cases of resected gallbladder carcinoma and found dysplasia adjacent to carcinoma in 46 of the 110 cases, and this change was frequently found in lesions at an early stage and in well-differentiated carcinoma (level V).Fig. 1Macroscopic photograph of adenoma of the gallbladderFig. 2a--cHistological examination of adenoma of the gallbladder. **a** Low magnification; **b** intermediate magnification; **c** high magnification (H&E)

Kubota et al.[@CR23] reported that in patients with polypoid lesions of the gallbladder, the respective diameters of adenomas and cancers were 6.9 mm (range, 4 to 13 mm) and 25.7 mm (range, 5 to 50 mm). In that study, 75% of the adenomas and 13% of the cancers had a diameter of less than 10 mm. It has also been reported that when a polypoid lesion of the gallbladder is sessile, has a diameter greater than 10 mm, and /or grows rapidly, it is highly likely to be cancerous.[@CR23]--[@CR25] In such cases, surgical resection should be recommended.

Adenomyomatosis (Fig. [3](#Fig3){ref-type="fig"}; [4](#Fig4){ref-type="fig"}) {#Sec10}
-----------------------------------------------------------------------------

Adenomyomatosis has not been considered to have malignant potential.[@CR1] Nabatame et al.[@CR9] studied the relationship between adenomyomatosis and gallbladder cancer by examining 4560 gallbladders (2031 from male patients and 2529 from female patients; age 14 to 94 years) resected for gallbladder cancer, gallstones, or other diseases. In that study, the incidence of gallbladder carcinoma was higher in patients with segmental adenomyomatosis (22/334; 6.6%) than in those without (181/4226; 4.3%; *P* = 0.049). This difference was more marked in patients equal to or older than 60 years of age (*P* \< 0.001). However, the magnitude of risk for gallbladder cancer in patients with adenomyomatosis has not been clearly established.[@CR1],[@CR26]Fig. 3a--cFindings in adenomyomatosis. **a** Fundal type: circumscribed hypertrophy of the fundus of the gallbladder with Rokitansky-Aschoff sinus. Case complicated by cholecystolithiasis. *Upper*, resected specimen; *lower left*, abdominal computed tomography (CT; cross section); *lower right*, abdominal CT (sagittal section). **b** Segmental type: hypertrophy circumscribing the gallbladder with Rokitansky-Aschoff sinus. *Upper*, resected specimen; *lower left*, abdominal computed tomo graphy (CT; cross section); *lower right*, abdominal CT (sagittal section). **c** Diffuse (segmental-diffuse) type: hypertrophy and Rokitansky-Aschoff sinus from the gallbladder body to the fundus. Gallstones in the fundus. *Left*, resected specimen; *right*, abdominal CTFig. 4This Loupe image shows growing and dilating Rokitansky-Aschoff sinuses from the muscularis propria to the subserosa, and the growing smooth muscle fiber and collagen fiber surrounding them (H&E)

Risk factors for ampullary carcinoma {#Sec11}
====================================

Kimura et al.[@CR27] histologically investigated the papilla of Vater in 576 autopsy cases of elderly people and revealed that the incidences of group 3 and 4 epithelia in the common channel were significantly higher than those in the intraduodenal portion of the bile duct, pancreatic duct, or duodenal epithelia. They also investigated resected specimens from the patients with carcinoma of the papilla of Vater and found tha the common channel was the most frequent site for the possible origin of carcinoma (level IV). These results suggest that the common channel is the most important site in the pathogenesis of carcinoma of the papilla of Vater. With regard to the incidence of "adenoma" surrounding carcinoma of the papilla of Vater, the values have been reported to range from 82% to 91%[@CR27] (level IV). Therefore, the adenoma-carcinoma sequence is very important in the pathogenesis of carcinoma of the papilla of Vater. In addition, familial adenomatous polyposis (FAP) is notable for the risk of adenoma in the ampulla of Vater.

Side memo 1 Primary sclerosing cholangitis (PSC) {#Sec12}
================================================

Definition: recurrent or persistent chronic inflammatory disease of extra- and intrahepatic bile ducts resulting in obliterative fibrosis. No effective treatment has been discovered to date, and liver transplant is required in the terminal stage. Although autoimmune abnormality is suspected, the underlying pathogenesis is still unknown. Fig. 5Endoscopic retrograde cholangiopancreatography image of PSC. Multifocal stricturing of intrahepatic and extrahepatic bile ducts, and shaggy appearance of extrahepatic bile ducts

Diagnostic criteria {#Sec13}
-------------------

Typical radiological findingsTypical radiological findings of bile duct are;Multifocal stricturing Beaded appearance; short or/and annular strictures interspersed among normal or slightly inflamed ducts. This appearance is thought to reflect the fibrous stricture portions and the normal segments of the bile duct. One-fifth of the cases present band-like strictures that are extremely short, and one-fourth present diverticulum-like outpouchingsPruned-tree appearance; diminished arborization of the intrahepatic ductsShaggy appearance; diffuse mural irregularities of extrahepatic bile ductsTypical clinical presentationImportant clinical history: inflammatory bowel disease, bile obstructionBlood examination: high alkaline phosphatase (ALP; two or three times upper limit of normal) for 6 months or moreDeductive diagnosisExclude secondary sclerotic cholangitis as follows: Infectious cholangitis due to AIDSMalignant neoplasms or similar disease in the bile duct (excluding PSC accompanied by early-stage cholangiocarcinoma)Previous surgery of the biliary tract (excluding cholecystectomy)Bacterial cholangitis accompanying biliary tract stricturing or biliary calculusIschemic cholangitis due to floxuridine

Side memo 2 Diagnostic criteria of pancreaticobiliary maljunction (PBM; see Fig [6](#Fig6){ref-type="fig"}) {#Sec14}
-----------------------------------------------------------------------------------------------------------

Definition: PBM is a congenital anomaly consisting of a union of the pancreatic and bile ducts located outside the duodenal wall.Fig. 6a,bEndoscopic retrograde cholangiopancreatography (ERCP) image of pancreaticobiliary maljunction (PBM): a patient with congenital bile duct dilatation (Kotani IV a type). **a** The pancreatic duct joins the biliary duct. **b** Pancreaticobiliary maljunction without bile duct dilatation (Fig 6a, with permission from Koyanagi K, Aoki T, editors. *Pancreaticobiliary maljunction*. Tokyo: Igaku Tosho Shuppan: 2002. p 25, Fig. [4](#Fig4){ref-type="fig"}[@CR29])

Diagnostic criteria: PBM is diagnosed by either radiological or anatomical findings

### 1) Radiological findings {#Sec15}

It is necessary to confirm the lack of sphincter action at the union of the pancreatic and bile ducts. However, because clarification of the lack of sphincter action is often difficult, the following radiological findings of endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTHC), intraoperative cholangiography, or similar methods are used to verify whether there is a long common channel or a complicated confluence of the pancreatic and bile ducts.

### 2) Anatomical findings {#Sec16}

Confirm the abnormal anatomical confluence of the pancreatic and bile ducts outside the duodenal wall or confirm the complicated confluence by surgery, autopsy, or other procedures.

CQ 2 Is prophylactic treatment necessary for pancreaticobiliary maljunction (PBM)? {#Sec17}
==================================================================================

PBM with bile duct dilatation is a risk factor for bile duct and gallbladder cancer. Prophylactic excision of the gallbladder and common bile duct should be recommended for PBM with bile duct dilatation (recommendation grade C1)

PBM without bile duct dilatation is a risk factor for gallbladder cancer. A prophylactic cholecystectomy is the appropriate surgical procedure for PBM without bile duct dilatation. (recommendation grade B)

As mentioned above, a retrospective nationwide survey (1990 to 1999) of PBM revealed that the incidence of biliary tract cancer was 10.6% in the group with bile duct dilatation; of these biliary tract cancers, 64.9% were gallbladder carcinoma and 33.6% were bile duct cancer.[@CR3] Therefore, PBM with bile duct dilatation should be considered as a risk factor for bile duct cancer and gallbladder cancer, and in these patients, prophylac tic excision of the gallbladder and extrahepatic bile duct should be considered. Currently, standard prophylactic treatment of PBM with bile duct dilatation consists of cholecystectomy, extrahepatic biliary duct resection, and hepatocholangiojejunostomy.[@CR28]

In the PBM patients without bile duct dilatation, the incidence of biliary tract cancer was 37.9%, and 93.2% of these patients had gallbladder cancer[@CR3] (level IV). These reports suggest that PBM without bile duct dilatation should be considered as a risk factor for gallbladder cancer. Therefore, in these patients, excision of the gallbladder should be considered as a minimal prophylactic treatment. Controversy remains as to whether prophylactic bile duct resection is necessary in PBM patients without bile duct dilatation. It has been reported that the long-term results of a prophylactic cholecystectomy without bile duct resection for PBM patients without bile duct dilatation were acceptable[@CR29],[@CR30] (level IV). Also, it has been reported that *K-ras* gene mutation is frequent in the mucosa of the bile duct in PBM patients with bile duct dilatation, while no mutation is observed in PBM patients without bile duct dilatation[@CR31] (level IV). These reports support a prophylactic cholecystectomy without bile duct resection as being the best treatment option for PBM patients without bile duct dilatation. In contrast, it has been reported that the incidence of bile duct cancer in PBM patients without bile duct dilatation is lower than that in PBM patients with bile duct dilatation, but the incidence seems higher than that in healthy controls[@CR3],[@CR32] (level IV). Moreover, it has been reported that *K-ras* and *p53* gene mutations are found frequently even in the nondilated bile duct in patients with PBM[@CR33] (level IV). These reports support the possibility that complete excision of the common bile duct may be needed to decrease the risk of bile duct cancer.

CQ 3 Is a cholecystectomy required for asymptomatic cholecystolithiasis? {#Sec18}
========================================================================

A cholecystectomy is not advised for asymptomatic cholecystolithiasis (recommendation grade C2)

It has been well established that gallstones are associated with gallbladder cancer[@CR1],[@CR8] (level V). Not only is there an increased prevalence of gallbladder cancer in patients with gallstones but up to 75% of patients with gallbladder cancer have been noted to have had gallstones. [@CR1] It has also been reported that a stone size of more than 3 cm, a family history of gallbladder cancer, and the duration of cholelithiasis are potential risk factors for the development of gallbladder cancer.[@CR1],[@CR14]--[@CR16] However, there is no evidence of a direct causal relationship between gallstones and gallbladder cancer. Maringhini et al.[@CR34] followed-up, for more than 31 000 person-years a total of 2583 residents of Rochester, Minnesota, who had gallstones. Gallbladder cancer developed in 5 patients after a median follow-up of 13.3 years. The incidence of gallbladder cancer was significantly higher than expected for men but not for women (153 vs 18 per 100 000 person-years). However, these authors do not recommend cholecystectomy, because the absolute incidence and the total numbers of men and women who developed gallbladder cancer were low. Moreover, Gracie and Ransohoff[@CR17] followed up the subsequent history of 123 patients with asymptomatic gallstones for 10 years or longer, and revealed that there was no case of gallbladder cancer reported among that group. This low rate of cancer development in asymptomatic patients with gallstones is similar to that noted in other reports (0.01%/year--0.02%/year)[@CR1],[@CR35] and, in general, this low rate has lent support to the practice of not performing prophylactic cholecystectomy in patients with asymptomatic cholelithiasis.

Controversy remains as to whether patients with calcification of the wall of the gallbladder, referred to as "porcelain gallbladder" carry a risk of gallbladder cancer. It has been reported that porcelain gallbladder is often complicated by gallbladder carcinoma[@CR18],[@CR19] (level IV). However, Towfigh et al.[@CR20] have reported that porcelain gallbladder is not associated with gallbladder carcinoma (level IV). The pathogenic mechanism underlying the relationship of calcification to gallbladder cancer also remains unknown.

CQ 4 Is a cholecystectomy necessary for polypoid lesions of the gallbladder (see side memo 3) {#Sec19}
=============================================================================================

When a polypoid lesion of the gallbladder is sessile, has a diameter greater than 10 mm, and/or grows rapidly, it is highly likely to be cancerous and should be resected (recommendation grade B)

Currently, adenoma and dysplasia have been regarded as a precancerous lesions of the gallbladder.[@CR21] Intestinal and gastric metaplasia seems to be the pathway through which the epithelial dysplasia is produced.[@CR21],[@CR22] Yamagiwa[@CR22] examined 110 cases of resected gallbladder carcinoma and revealed that dysplasia adjacent to carcinoma was found in 46 of the 110 cases, and this change was frequently found in lesions at the early stage and in well-differentiated carcinoma (level V).

Kubota et al.[@CR23] evaluated 72 patients who underwent cholecystectomy for polypoid lesions of the gallbladder. In that study, histological examination showed cholesterol polyps in 47 patients, adenoma in 8, cancers in 16, and an inflammatory polyp in 1. The respective diameters of the adenomas and cancers were 6.9 mm (range, 4 to 13 mm) and 25.7 mm (range, 5 to 50 mm); 75% of the adenomas and 13% of the cancers had a diameter of less than 10 mm (level IV). Chijiiwa and Tanaka[@CR36] also examined 44 patients who underwent cholecystectomy for polypoid lesions of the gallbladder, and reported that the sex ratio, symptoms, and the presence of gallstones were not significantly different between patients with carcinoma and those with benign polypoid lesions, and that the size (\>10 mm), number of polypoid lesions (single), and age (\> or =60 years) were significant indicators of carcinoma.

It has been reported that when a polypoid lesion of the gallbladder is sessile, has a diameter greater than 10 mm, and/or grows rapidly, it is highly likely to be cancerous[@CR23]--[@CR25],[@CR36]--[@CR39] (level IV). In such cases, surgical resection should be considered.

Side memo 3 Polypoid lesions of the gallbladder (see Figs. [7](#Fig7){ref-type="fig"}--[10](#Fig10){ref-type="fig"}) {#Sec20}
====================================================================================================================

Definition: "Polypoid" is the general term for torous lesions protruding into the lumen of the gallbladder, no matter whether they are neoplastic or nonneoplastic. The majority of polypoid lesions are nonneoplastic lesions such as cholesterol polyp, adenomyomatosis, or inflammatory polyp. Benign neoplastic lesions include adenoma and metaplastic polyp, while malignant neoplastic lesions include gallbladder cancerFig. 7Ultrasound image of a cholesterol polyp: sessile polyp that has a higher echoic signal than the liverFig. 8Ultrasound image of adenoma of the gallbladder: this image indicates a semipedunculate polyp with isoechoic signalFig. 9Ultrasound image of early-stage gallbladder carcinoma: a pedunculated protrusion with a relatively high echoic signal. Depth of tumor invasion is limited to the mucosal layerFig. 10Ultrasound image of gallbladder carcinoma: sessile protruding lesion. Depth of tumor invasion is to the subserosa
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